Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTV04C Recombinant Herpes Zoster Vaccine in Healthy Adults
NCT06801509Phase 2Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Feb 2025
- Primary completion
- Nov 2025
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SCTV04C in herpes zoster (HZ) (5 arms), sponsored by Sinocelltech Group Limited. Primary endpoints: Incidence and intensity of solicited adverse events, Incidence and intensity of unsolicited adverse events and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
SCTV04C
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06801509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801509.